DRA will be open normally over the Christmas period only closing on the public holidays.
We have further strengthened our Regulatory team with the welcome addition of Regulatory Expert, Mirjam Linnanen B.Sc. (Pharm.).
The congress is a forum for health care researchers, health technology assessors, manufacturers, governments, and patients to debate health care decision-making policies & processes.
Meet face-to-face with international pharmaceutical companies and remain one step ahead of a constantly changing pharmaceutical market.
According to the new guidelines, all sites involved in the manufacture of the active substance must be included in the CEP.
DRA is pleased to announce that Svetlana Fedorova B.Sc. (Pharm.) has joined our Regulatory team as Regulatory Expert.
According to the new Pharmacovigilance Legislation, all new marketing authorisation applications must contain a Risk Management Plan (RMP).
DRA reinforced its translation team in June with the appointment of Seija Anttila (BA).
The European Medicines Agency (EMA) has published the initial list of medicines that are subject to additional monitoring.
Jenni Hannukainen attended the conference “The New FDA/EU Approach to Process Validation” on 23-24 April in Denmark.
We regularly survey the status of our clientships and collect feedback to develop our activities.
EuDRAcon is a pan-European network of regulatory affairs consultancy companies and its annual meeting begins today at DRA and then continues in Finnish Lapland.